DeNovix becomes sponsor at Tufts Launchpad BioLabs

DeNovix becomes sponsor at Tufts Launchpad BioLabs

DeNovix Inc. is the newest sponsor at Tufts Launchpad | BioLabs with the placement of two key pieces of laboratory instrumentation. DeNovix has provided a CellDrop™ FL Automated Cell Counter and a DS-11 FX+ Spectrophotometer / Fluorometer for use by the facility’s resident companies. Scientists at Tufts Launchpad | BioLabs test the DS-11 FX+ Spectrophotometer. Tufts Launchpad | BioLabs is a fully equipped, co-working and shared lab space that provides startups with the infrastructure and equipment needed to build their biotechnology companies. Tufts Launchpad | BioLabs is designed to be Boston’s premier co-working facility for life science startups. Launched in 2018, the facility currently is home to 24 companies. Support from industry-leading sponsors like DeNovix helps our resident companies to have access to state-of-the-art equipment to allow them to generate meaningful data essential to their research programs. DeNovix provides practical and robust equipment designed to minimize the use of consumables without compromising results.” Dr. Christine Kressirer, Site Director of Tufts Launchpad | BioLabs and an employee of BioLabs Less than a decade ago, DeNovix was a start-up company with a handful of people and some great ideas. Tufts Launchpad | BioLabs is a thriving innovation center and we want to help their resident companies by placing state-of-the art DeNovix equipment at their fingertips. Both CellDrop and the DS-11 Series are used in a number of life science workflows, so we know both instruments will be involved in helping start-ups convert their ideas into successful companies.” Kevin Kelley, DeNovix Business Director Tufts Launchpad | BioLabs now able to count cells without costly plastic slides thanks to the DeNovix CellDrop FL Automated Cell Counter. Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More